SCHEMBL26884349

SCHEMBL26884349

Cc1ccc(-c2csc(NC(=O)c3cc(F)ccn3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.61
▸ MEN1 O00255 4/20 0.61
▸ HTT P42858 3/20 0.61
▸ MAPT P10636 3/20 0.61
▸ POLB P06746 2/20 0.61
▸ ALDH1A1 P00352 2/20 0.61
▸ CDC25A P30304 1/20 0.61
▸ CDC25B P30305 1/20 0.61
▸ CDC25C P30307 1/20 0.61
▸ ESR1 P03372 1/20 0.61
▸ ESR2 Q92731 1/20 0.61
▸ HSD17B10 Q99714 1/20 0.61
▸ LMNA P02545 5/20 0.58
▸ SMN1; SMN2 Q16637 4/20 0.58
▸ NPC1 O15118 3/20 0.58
▸ RAB9A P51151 3/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ GSTO1 P78417 1/20 0.55
▸ CCR6 P51684 1/20 0.54
▸ WNT3A P56704 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22728560 0.89 MEN1 (0.62) KMT2AMEN1HTTMAPTPOLB
SCHEMBL26884355 0.85 KMT2A (0.66) KMT2AMEN1HTTMAPTPOLB
SCHEMBL22728474 0.84 MAPT (0.59) KMT2AMEN1HTTMAPTPOLB
SCHEMBL12248896 0.83 ADORA3 (0.68) KMT2AMEN1HTTMAPTPOLB
SCHEMBL22728481 0.82 LMNA (0.64) KMT2AMEN1HTTMAPTPOLB
SCHEMBL26884100 0.81 POLB (0.70) KMT2AMEN1HTTMAPTPOLB
SCHEMBL22728558 0.81 MPL (0.69) KMT2AMEN1HTTMAPTPOLB
SCHEMBL22728498 0.81 LMNA (0.78) KMT2AMEN1HTTMAPTPOLB
SCHEMBL5732893 0.81 KMT2A (0.67) KMT2AMEN1HTTMAPTPOLB
SCHEMBL12249200 0.81 POLB (0.60) KMT2AMEN1HTTMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 KMT2A 4379/4885MEN1 4814/4885HTT 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback